These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8523405)

  • 1. 3D-quantitative structure-activity relationships of human immunodeficiency virus type-1 proteinase inhibitors: comparative molecular field analysis of 2-heterosubstituted statine derivatives-implications for the design of novel inhibitors.
    Kroemer RT; Ettmayer P; Hecht P
    J Med Chem; 1995 Dec; 38(25):4917-28. PubMed ID: 8523405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
    Debnath AK
    J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.
    Matter H; Schwab W; Barbier D; Billen G; Haase B; Neises B; Schudok M; Thorwart W; Schreuder H; Brachvogel V; Lönze P; Weithmann KU
    J Med Chem; 1999 Jun; 42(11):1908-20. PubMed ID: 10354399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
    Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
    Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
    Opera TI; Waller CL; Marshall GR
    Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules.
    Waller CL; Oprea TI; Giolitti A; Marshall GR
    J Med Chem; 1993 Dec; 36(26):4152-60. PubMed ID: 8277496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.
    Pérez C; Pastor M; Ortiz AR; Gago F
    J Med Chem; 1998 Mar; 41(6):836-52. PubMed ID: 9526559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking and QSAR studies on substituted acyl(thio)urea and thiadiazolo [2,3-alpha] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase.
    Sun J; Cai S; Mei H; Li J; Yan N; Wang Q; Lin Z; Huo D
    Chem Biol Drug Des; 2010 Sep; 76(3):245-54. PubMed ID: 20626407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease.
    Avram S; Bologa C; Flonta ML
    J Mol Model; 2005 Mar; 11(2):105-15. PubMed ID: 15714296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes.
    Oprea TI; Waller CL; Marshall GR
    J Med Chem; 1994 Jul; 37(14):2206-15. PubMed ID: 8035428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity.
    Scholz D; Billich A; Charpiot B; Ettmayer P; Lehr P; Rosenwirth B; Schreiner E; Gstach H
    J Med Chem; 1994 Sep; 37(19):3079-89. PubMed ID: 7932531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
    Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
    Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
    Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A
    Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docking-based 3D-QSAR study of pyridyl aminothiazole derivatives as checkpoint kinase 1 inhibitors.
    Balupuri A; Balasubramanian PK; Gadhe CG; Cho SJ
    SAR QSAR Environ Res; 2014; 25(8):651-71. PubMed ID: 24911214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
    Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
    SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
    Reich SH; Melnick M; Pino MJ; Fuhry MA; Trippe AJ; Appelt K; Davies JF; Wu BW; Musick L
    J Med Chem; 1996 Jul; 39(14):2781-94. PubMed ID: 8709109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative molecular field analysis (CoMFA) of a series of symmetrical bis-benzamide cyclic urea derivatives as HIV-1 protease inhibitors.
    Debnath AK
    J Chem Inf Comput Sci; 1998; 38(4):761-7. PubMed ID: 9691478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.